Business
Appointment digital asset treasury partner Archax
Shortwave Life Sciences PLC, a healthcare company focused on anorexia nervosa treatments, has appointed Archax Ltd as its digital asset exchange, broker, and custodian. This decision follows a comprehensive business review initiated in July to strengthen the company's strategic framework for growth, specifically regarding its digital asset treasury management. Shortwave Life Sciences will seek shareholder approval at its upcoming Annual General Meeting to activate a digital asset treasury management policy. The company selected Archax due to its FCA regulation across the range of digital asset services required. Disclaimer*
About this update from Tomahawk Metals Plc
[{"type":"text","content":"\n\nSHORTWAVE LIFE SCIENCES PLC\n \n(\"Shortwave\" or \"the Company\")\n \n \n26th September 2025\nCompany appoints digital asset treasury management partner Archax\n \nShortwave Life Sciences PLC (PSY), quoted on the Aquis Stock Exchange Growth Market, the UK's leading healthcare company focused on developing innovative treatments for anorexia nervosa, is pleased to announce the appointment of Archax Ltd as exchange, broker and custodian of digital assets.\n \nIn July the Company announced it would complete a comprehensive business review to strengthen its strategic framework for growth. As part of its digital asset treasury management strategy the Company reviewed a range of digital asset partners and appointed Archax. The Company has now completed the onboarding process.\n \nThe Company will now progress calling its Annual General Meeting, to seek shareholder approval to commence activating a digital asset treasury management policy, amongst other ordinary resolutions to be put to shareholders.\n \nExecutive Director Stephen Molloy said \"Archax are explicitly FCA-regulated across the range of digital asset services we require, to provide us the level of institutional-grade protection and client services we look for from our partners\".\nAbout Shortwave Life Sciences: \nShortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.\n \nThe Directors of the Company accept responsibility for the contents of this announcement.\n \nFor media inquiries, please contact:\n \nEnquiries:\n \nCompany:\nRolf Gerritsen\n+44 20383 87621\n \n Peterhouse Capital Limited:\nCorporate Adviser:\n+ 44 (0) 20 7469 0930\n \nCorporate Broker:\n+44 (0) 20 7220 9797\n&n...